drugset / Trial / NCT04407234

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

NCT04407234

Phase 1 Completed 36 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes. The study will last about 13 weeks for each participant, including screening.

Timeline

Start
2020-09-15
Primary completion
2021-01-07
Completion
2021-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 15 mg Subcutaneous
Background Acetaminophen Small molecule 160 mg Oral